Propanc Biopharma, Inc. (PPCB): Nasdaq/NYSE listing notice — Nasdaq notifies Propanc Biopharma of non-compliance with $1.00 minimum bid price rule

Propanc Biopharma, Inc.

Notice received Dec 31, 2025; bid price below $1.00 for 35 consecutive business days.
Compliance deadline June 30, 2026; must close at $1.00+ for 10 consecutive days.
If not cured, may get additional 180 days with conditions; else delisting.
Delisting could reduce liquidity, limit equity financing, impair employee incentives.
Company evaluating options to regain compliance; no specific plan announced.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Propanc Biopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 31, 2025, Propanc Biopharma, Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “ Bid Price Requirement ”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bi

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Propanc Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-000834

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.